healthcare professionals
Product areas
Consumer health
Pain relief
Cough & cold
Gastro
Other
Specialty Pharma
Dermatology
Woundcare
Womens health
Urology
Obesity
Medical Nutrition
Protein
Glycogen Storage Disease (GSD)
Fat Metabolism
Renal
Nutritional support
Ketogenic Diet (KD)
Branded generics
Cardiology
Antibiotics
Business development
Business Model
Quality
Local knowledge
Our partners
Investors
Stock exchange news
Navamedic share
Annual General Meeting
Top 20 shareholders
Financial results
Annual reports
Prospectus
Financial calendar
Corporate governance
About
Contact
Vacant positions
Press
Management
Board of directors
EFPIA Disclosure code
Product areas
Consumer health
Pain relief
Cough & cold
Gastro
Other
Specialty Pharma
Dermatology
Woundcare
Womens health
Urology
Obesity
Medical Nutrition
Protein
Glycogen Storage Disease (GSD)
Fat Metabolism
Renal
Nutritional support
Ketogenic Diet (KD)
Branded generics
Cardiology
Antibiotics
Business development
Business Model
Quality
Local knowledge
Our partners
Investors
Stock exchange news
Navamedic share
Annual General Meeting
Top 20 shareholders
Financial results
Annual reports
Prospectus
Financial calendar
Corporate governance
About
Contact
Vacant positions
Press
Management
Board of directors
EFPIA Disclosure code
Press
Contact
Vacant positions
Press
Antibiotics in the Nordics
Icepharma new distributor of antibiotics to the Icelandic market
ThermaCare®
Update Covid-19
Management
EFPIA Disclosure code
Norway
Board of directors
Navamedic ASA: Q1 2021 financial
“In the first quarter of 2021, we continued to deliver growth in our underlying portfolio. The rapid growth of specialty pharma product Mysimba and the
Navamedic ASA: Q4 2020 financial results
“The fourth quarter of 2020 displayed strong growth in our underlying portfolio and new products introduced during the second half of the year. Key growth
Navamedic ASA: Q3 2020 financial results
“In the third quarter of 2020, we delivered strong growth driven by both the addition of new products such as ThermaCare and positive performance in
MyControl Support – A brand new support program for patients with obesity
Today, Navamedic launches MyControl Support in Sweden – a completely new support program aimed for people with obesity. This is a first of its kind
MyControl – A new website to raise awareness about obesity among healthcare professionals and patients
This is the first step in a wave of communication as part of Navamedic’s effort to increase knowledge about obesity, and to address the fact
Navamedic ASA: Q1 2020 financial results
“We had a solid start to the year delivering revenue growth across all key categories, displaying the attractiveness of the product portfolio and the value
Navamedic ASA: Annual report 2019
Oslo, 30 April 2020 – Navamedic ASA (OSE: NAVA) has published its annual report for 2019. The annual report is attached to this stock exchange
Navamedic ASA: Enters into distribution agreement for ThermaCare® with Angelini Pharma
“We are pleased to announce the agreement with Angelini Pharma for ThermaCare, expanding our portfolio of high-quality products to the benefit of our customers in
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
Privacy policy
